Trials evaluating the omission of completion axillary-lymph-node dissection in patients with clinically node-negative breast cancer and sentinel-lymph-node metastases have been compromised by limited ...
Omitting axillary lymph node dissection does not increase the risk for recurrence or compromise 5-year overall survival outcomes in patients with early-stage, node-negative breast cancer with sentinel ...
Recently, omission of axillary lymph node dissection among patients with early breast cancer has been found to have no detrimental effect on outcomes in most cases, continuing a trend toward less ...
Neoadjuvant chemotherapy (NAC) is one of the standard-of-care therapies for breast cancer (BC) with axillary lymph node (ALN) metastases. However, the response to this therapy varies depending on the ...
Women with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer who have one positive sentinel node and no high-risk features can likely be spared ...
Trends and outcomes in patients receiving neoadjuvant chemotherapy for breast cancer in Ontario: A population-based study. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This ...
Targeted axillary dissection (TAD) is a relatively new breast cancer procedure. It allows surgical oncologists to specifically locate a lymph node that contained cancer before chemotherapy, remove it ...
Sentinel lymph node (SLN) resection has been advocated as an option to reduce morbidity for women undergoing surgery for breast cancer. When the sentinel node is negative for breast cancer, SLN ...
There is not enough evidence about how well this procedure works in the long term or how it affects quality of life for people with breast cancer. But there are no major safety concerns. So, it can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results